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Abstract: Hyperkalaemia burden in non-dialysis chronic kidney disease (CKD) under nephrology
care is undefined. We prospectively followed 2443 patients with two visits (referral and control
with 12-month interval) in 46 nephrology clinics. Patients were stratified in four categories of
hyperkalaemia (serum potassium, sK ≥ 5.0 mEq/L) by sK at visit 1 and 2: Absent (no-no), Resolving
(yes-no), New Onset (no-yes), Persistent (yes-yes). We assessed competing risks of end stage kidney
disease (ESKD) and death after visit 2. Age was 65 ± 15 years, eGFR 35 ± 17 mL/min/1.73 m2,
proteinuria 0.40 (0.14–1.21) g/24 h. In the two visits sK was 4.8 ± 0.6 and levels ≥6 mEq/L
were observed in 4%. Hyperkalaemia was absent in 46%, resolving 17%, new onset 15% and
persistent 22%. Renin-angiotensin-system inhibitors (RASI) were prescribed in 79% patients. During
3.6-year follow-up, 567 patients reached ESKD and 349 died. Multivariable competing risk analysis
(sub-hazard ratio-sHR, 95% Confidence Interval-CI) evidenced that new onset (sHR 1.34, 95% CI
1.05–1.72) and persistent (sHR 1.27, 95% CI 1.02–1.58) hyperkalaemia predicted higher ESKD
risk versus absent, independently from main determinants of outcome including eGFR change.
Conversely, no effect on mortality was observed. Results were confirmed by testing sK as continuous
variable. Therefore, in CKD under nephrology care, mild-to-moderate hyperkalaemia status is
common (37%) and predicts per se higher ESKD risk but not mortality.
Keywords: CKD; ESKD; death; anti-RAS; hyperkalaemia; competing risk
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1. Introduction
Chronic hyperkalaemia is common in non-dialysis chronic kidney disease (ND-CKD).
Recent observational studies have reported a greater prevalence of high serum potassium (sK) in this
population than in general population; however, the reported rates have been extremely variable—from
1% to 50%—being mainly dependent on GFR and comorbidities of included patients, as on the
number of sK measurements [1–7]. This latter aspect is crucial because prevalence of hyperkalaemia
increases with the number of sK tests, thus indicating that identification of true hyperkalaemia
cannot be based on a single sK value [6].
More important, an additional lack of solid information on hyperkalaemia burden in CKD is the
prognostic role. Indeed, while in unselected population hyperkalaemia poses a risk excess of mortality
for even moderate increases of sK (≥5.0 mEq/L) [7–13], the association between hyperkalaemia and
progression to end-stage kidney disease (ESKD) remains controversial [1,4,10,13–15]. Gaining insights
into this association is essential because a main determinant of hyperkalaemia is the prescription of
inhibitors of renin-angiotensin-system (RASI) [16,17], that are the first-choice antihypertensive
agents in CKD due to the nephroprotective efficacy [18]. In this regard, it is interesting that RASI
withdrawal driven by hyperkalaemia increases mortality of patients seen in the general medicine
setting [17,19]. A vicious circle may similarly ensue with hyperkalaemia onset and dependent non-use
or withdrawal of RASI leading to ESKD. Increased awareness of this phenomenon and adequate
management of hyperkalaemia through dietary and/or pharmacological intervention may interrupt
this circle [20–22].
To date, no detailed study has evaluated the effect of hyperkalaemia on ESKD in outpatient
nephrology clinics. On the contrary, this evaluation is critical for several reasons. First, this is
the reference of care for high-risk CKD patients. Second, in patients referred to nephrology ESKD
overcomes mortality at variance with unselected CKD population [23,24]. Third, nephrologists
prescribe RASI, potentially associated with high sK [22], to most patients in order to slow down
CKD progression [22–26]. Fourth, in this specific setting a progressive decline of renal function, main
determinant of sK increase, is more commonly observed with respect to other clinical settings [23,24].
Finally, novel K binders have been now developed to treat chronic hyperkalaemia and improve
effectiveness of RASI therapy [21,22]; therefore, knowing the hyperkalaemia burden in renal clinics,
where these new drugs will be largely used, becomes a preliminary but essential step.
To fill this important gap of knowledge, we studied a large prospective cohort of ND-CKD patients
under stable nephrology care to verify in outpatient CKD clinics (I) the prevalence of hyperkalaemia
at referral and after 12 months, (II) the hyperkalaemia-related risk of ESKD and all-cause death in
the subsequent period of follow up. To gain a proper analysis of the effect of sK on kidney survival,
the effect of exposure was evaluated by competing risk analysis to take into account the potential
occurrence of death before ESKD. Analyses were adjusted for major confounders, including RASI
prescription and eGFR change in the first year of nephrology care.
2. Materials and Methods
This is a multicentre prospective study pooling data from four established cohorts (Figure 1).
Cohorts included ND-CKD patients (eGFR < 60 mL/min/1.73 m2 or proteinuria >0.15 g/24 h)
under stable care in Italian outpatients nephrology clinics to gain information on clinical features and
outcome of referred CKD. Methodological details are described in the published papers [23,25–27] and
here summarized in Appendix. To the aims of this study, we excluded duplicate patients, those with
missing sK level as patients with only referral visit.
We grouped patients according to the presence of hyperkalaemia, defined as serum K≥ 5.0 mEq/L
in the two study visits: no hyperkalaemia in either visit (absent), hyperkalaemia only at visit 1
(resolving), or only at visit 2 (new onset), or at both visits (persistent). Similar categories were created
for RASI prescription: both visits, only visit 1, only visit 2, neither visit.
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Endpoints of the study were ESKD, that is, start of chronic dialysis therapy (>30 days) or kidney
transplantation and all-cause death before ESKD, as derived by national registries. For survival
analyses, patients were followed from visit 2 up to ESKD, all-cause death, or 31 December 2015 and




Figure 1. Study flow chart. 
2.1. Statistics 
Continuous variables are reported as either mean ± standard deviation (SD) or median and 
interquartile (IQR) range based on their distribution. Comparison among hyperkalaemia categories 
was assessed by ANOVA or Kruskal-Wallis test, while changes in each category across two visits 
were performed by paired Student’s t-test or paired Wilcoxon test. Categorical variables are reported 
as percentage and were analysed using a Chi-square test or McNemar test to evaluate changes across 
two visits.  
Follow-up for survival analyses started at visit 2 and median follow-up value was estimated by 
inverse Kaplan-Meier approach. Incidence rates of ESKD and death before ESKD were reported as 
number of events/person-time and 95% confidence interval (CI) calculated assuming a Poisson 
distribution. Risk of ESRD versus death in whole population was compared according to Kochar et 
al. [28]. 
Competing risk approach was used in the survival analysis because in ND-CKD, ESKD and 
death before ESKD are competing events, that is, occurrence of death prevents ESKD. The competing 
risk analysis must be considered when the absolute percentage of competing event is >10% [29]; in 
our population, in fact, death before ESRD occurred in 14.3%.  
In the univariate analysis we built and compared cumulative incidence curves among categories 
by using Gray test [30], while multivariable Fine and Gray model was used to estimate the sub-
distribution hazard ratio (sHR) and 95% CI [31].  
Models were stratified by cohort to consider potential differences in the basal risks across the 
four cohorts and were adjusted for the following potential risk factors of ESKD recorded at visit 2: 
age, gender, diabetes, body mass index (BMI), systolic blood pressure, cardiovascular (CV) disease 
history, haemoglobin, eGFR, 24-h proteinuria, categories of RASI, as well as the eGFR change 
between baseline (visit 1) and 12-month control (visit 2).  
To take into account the non-normal distribution of 24-h proteinuria and the non-linear 
association with outcomes, this covariate was log-transformed. Non-linear association of sK as 
continuous variable with outcomes was tested adding in the model the quadratic value of sK and 
retained if the coefficient was significant.  
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cohorts and r adjusted for the following potential risk factors of ESKD recorded at visit 2: ag ,
gender, diabetes, body mass in ex (BMI), systolic bl od pressure, cardiovascular (CV) disease history,
haemoglobin, eGFR, 24-h proteinuria, categories of RASI, as well as the eGFR change between baseline
(visit 1) and 12-m nth control (visit 2).
J. Clin. Med. 2018, 7, 499 4 of 13
To take into account the non-normal distribution of 24-h proteinuria and the non-linear association
with outcomes, this covariate was log-transformed. Non-linear association of sK as continuous variable
with outcomes was tested adding in the model the quadratic value of sK and retained if the coefficient
was significant.
A two-tailed P value < 0.05 was considered significant. Data were analysed using STATA
version 14 (Stata Corp. College Station, TX, USA) and Cmprsk, CrrSC packages of R software 3.3.1
(R Foundation for Statistical Computing, Vienna, Austria).
3. Results
3.1. Baseline Period
The whole cohort was originally composed by 2813 patients referred to 46 outpatient CKD clinics
in Italy. According to exclusion criteria, we studied 2443 patients (Figure 1). As compared with
included patients, those excluded because of missed visit 2 were older and had more severe disease,
while sK and use of RASI did not differ (Table S1).
Included patients still had a high-risk profile, as testified by the high prevalence of diabetes and
CV disease, the low eGFR value and the high BMI and blood pressure levels (Table 1).










Number (%) 2443 (100) 1121 (46) 415 (17) 363 (15) 544 (22)
Age (years) 65.1 ± 14.6 64.4 ± 15.2 66.6 ± 13.6 63.6 ± 15.4 66.4 ± 13.4 0.01
Males (%) 58 57 58 64 59 0.12
BMI (kg/m2) 27.8 ± 5.1 27.7 ± 5.0 27.8 ± 5.1 27.5 ± 4.8 28.1 ± 5.4 0.35
Diabetes (%) 28 26 28 29 31 0.15
CV disease (%) 36 35 37 36 36 0.86
Smoking (%) 13 13 15 13 12 0.68
eGFR (mL/min/1.73 m2) 35.0 ± 17.3 39.0 ± 19.3 33.1 ± 15.0 34.3 ± 16.7 28.6 ± 12.3 <0.001
Systolic BP (mmHg) 139 ± 20 139 ± 20 139 ± 20 139 ± 21 141 ± 19 0.281
Renal disease (%) <0.001
HTN 30 33 32 28 24
DKD 13 10 13 16 17
GN 17 19 15 15 15
TIN 9 10 9 10 8
PKD 5 5 5 5 6
Other 7 7 6 8 9
Unknow 19 17 20 19 22
BMI, body mass index; CV, cardiovascular; BP, blood pressure; HTN, hypertensive nephropathy; DKD, diabetic
kidney disease; GN, glomerulonephritis; TIN, tubulo interstitial nephropathy; PKD, polycystic kidney disease.
Continuous variables are reported as mean ± SD
Mean sK did not differ in the two visits (4.81 ± 0.62 and 4.80 ± 0.59 mEq/L, respectively).
Prevalence of hyperkalemia was similar at visit 1 (39%, 95% CI 37–41) and visit 2 (37%, 95% CI 35–39%)
(p = 0.266), and it was dependent on CKD stage (Figure 2). Severe hyperkalemia (sK ≥ 6 mEq/L) was
rare (4% at visit 1 and 3% at visit 2), as hypokalemia (sK < 3.5 mEq/L < 1% in the two visits), while
hyperkalemia was mild to moderate in the vast majority of cases (Figure 2).
When considering sK in the two visits, we found that 32% patients changed the hyperkalemia
status (Figure S1). New onset and persistent hyperkalemia categories accounted for 37% of population
(15% and 22% respectively) while hyperkalemia was never detected in 46% and resolving in 17%.
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Figure 2. Prevalence (% and 95% CI) of mild, moderate and severe hyperkalaemia by CKD stage at the
two study visits. Mild: serum K 5.0–5.4 mEq/L; Moderate: 5.5–5.9 mEq/L; Severe: ≥6.0 mEq/L.
As shown in Table 2, across hyperkalaemia categories, proteinuria and serum phosphate increased
from absent to persistent (p < 0.001), while haemoglobin and eGFR decreased (p < 0.001). The higher
proteinuria levels in new onset and persistent categories was probably due to higher prevalence of
diabetic kidney disease (Table 1). At visit 1, the number of antihypertensive drugs was 2.15 ± 1.23
per patient and increase to 2.42 ± 1.34 at visit 2 (p < 0.001). RASI prescription in the yperkalaemia
categories is reported in Table 2; ov rall, 79% of patients were prescribed RASI, the vast majority of
patients havi g this therapy at either visit while 11% were reated only at visit 1 and 9% only at visit 2.
Use of dual RAS blockade slightly increased overall (from 8% to 10%, p < 0.001) from visit 1 to 2.
Conversely, anti-aldosterone drugs were prescribed in <1% at either visit. The nephrologist intervention
also led to increased prescription of statin (from 32% to 38%) and epoetin (from 13% to 18%) (p < 0.001
for both), while intervention aimed at controlling extracellular volume (diuretic administration and/or
low salt diet-urinary Na excretion ≤100 mEq/24 h), was observed in 71% patients at visit 1 and
decreased to 56% at visit 2 (p < 0.001), likely due to improved BP control (Table 2).
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Table 2. Clinical characteristics of patients by hyperkalaemia status (sK ≥ 5.0 mEq/L) at visit 1 and 2.
Absent (No-No) (n = 1121) Resolving (Yes-No) (n = 415) New Onset (No-Yes) (n = 363) Persistent (Yes-Yes) (n = 544)
Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2
Systolic BP (mmHg) 139 ± 20 135 ± 19 * 139 ± 20 136 ± 19 * 139 ± 21 134 ± 19 * 141 ± 19 137 ± 18 *
Diastolic BP (mmHg) 80 ± 11 78 ± 11 * 79 ± 11 77 ± 10 * 80 ± 11 77 ± 10 * 79 ± 11 77 ± 10 *
Potassium (mEq/L) 4.38 ± 0.40 4.40 ± 0.37 5.32 ± 0.35 4.55 ± 0.31 4.57 ± 0.32 5.30 ± 0.30 5.47 ± 0.44 5.46 ± 0.42
Glucose (mg/dL) 104.4 ± 33.4 103.9 ± 32.3 112.6 ± 48.6 110.9 ± 39.6 106.7 ± 36.9 108.6 ± 43.5 108.9 ± 42.9 107.7 ± 37.4
Phosphate (mg/dL) ˆ 3.67 ± 0.78 3.71 ± 1.11 3.84 ± 0.75 3.78 ± 0.77 3.77 ± 0.74 3.84 ± 0.95 3.95 ± 0.79 4.02 ± 0.88 *
Haemoglobin (g/dL) ˆ 13.0 ± 1.8 12.9 ± 1.7 * 12.7 ± 1.8 12.7 ± 1.7 12.5 ± 1.7 12.5 ± 1.7 12.2 ± 1.7 12.2 ± 1.6
eGFR (mL/min/1.73 m2) ˆ 39.0 ± 19.3 38.3 ± 20.3 * 33.1 ± 15.0 33.6 ± 17.1 34.3 ± 16.7 31.4 ± 16.6 * 28.6 ± 12.3 25.8 ± 12.3 *
eGFR change (mL/min/year) ˆ −0.55 ± 10.66 1.13 ± 10.34 −2.93 ± 9.63 −2.90 ± 7.81
















None (%) 33 34 28 33 33 31 23 30
CEI or ARB (%) 60 55 65 60 58 57 70 60
Dual blockade (%) 7 11 7 7 10 13 7 10
Data are mean ± SD or median (IQR) or percentage of patients. BP, blood pressure; eGFR, estimated glomerular filtration rate by EPI equation; RASI, renin angiotensin system inhibitors;
CEI, converting enzyme inhibitor; ARB, angiotensin II receptor blocker. ˆ p < 0.05 for visit 1 and visit 2 among the groups. * p < 0.05 vs. Visit 1. ◦ RASI distribution differs between visit 1
and 2 for Absent and Persistent group.
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3.2. Survival Analysis
Survival analyses started after visit 2. During a median follow-up of 3.6 years (IQR 3.0–5.9),
we registered 567 ESKD and 349 all-cause death before ESKD, with incidence rate per 100 patient/years
being 6.4 (95% CI 5.8–6.9) and 3.9 (95% CI 3.5–4.3), respectively.
The unadjusted competing risk analysis showed that in the overall population the cumulative
incidence of ESKD was markedly higher than mortality throughout the entire follow up period
(Kochar test p-value < 0.001) (Figure 3).
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When examining the four groups, incidence of ESKD was similarly higher in new onset and
persistent hyperkalaemia versus absent and resolving group, while ortality did not differ (Figure 4).
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Figure 4. Cumulative incidence after visit 2 of ESKD (A) and all-cause death before ESKD (B),
by competing risk analysis, by hyperkalaemia category.
The multivari ble survival analysis examining the independent role of sK as continuous variable
showed that 1 mEq/L higher sK at visit 2 was associated with 20% higher risk of ESKD (HR 1.20, 95% CI
1.04–1.39, p = 0.014) with no effect on mort lity (HR 0.94, 95% CI 0.76–1.17, p = 0.57). The a sociation
bet en sK and outcomes was linear as testified by the non-significant effect of quadratic sK on
ESKD (p = 0.79) and deat (p = 0.52). Si ilarly, the sK change (mEq/L) in the two visits signific ntly
redicted ESKD (HR 1.24, 95% CI 1.05–1.46, p = 0.011) with a neutral effect on mor ality (HR 0.95,
95% CI 0.75–1.20, p = 0.65).
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Table 3 illustrates the incidence and multi-adjusted risks of ESKD and death in the four
hyperkalaemia categories. The crude incidence of ESKD progressively increased from absent to
persistent hyperkalaemia while the association with mortality was less evident. At multivariable
analyses, new onset and persistent hyperkalaemia were associated with significantly increased
risk of ESKD (full multi-adjusted models are reported in Table S2). Conversely, no association of
hyperkalaemia with death emerged. Hazards did not change when also the causes of CKD were
added to the survival models (sensitivity analysis).










100-pt-y (95%-CI) sHR (95%-CI)
Absent 188/1121 4.32 (3.72–4.98) Reference 147/1121 3.38 (2.85–3.97) Reference
Resolving 93/415 5.98 (4.83–7.33) 0.98 (0.72–1.33) 65/415 4.18 (3.23–5.33) 1.01 (0.73–1.36)
New-onset 105/363 8.23 (6.73–9.96) 1.34 (1.05–1.72) 51/363 4.00 (2.98–5.26) 0.94 (0.64–1.38)
Persistent 181/544 10.52 (9.04–12.17) 1.27 (1.02–1.58) 86/544 5.00 (3.99–6.17) 0.91 (0.67–1.25)
sHR, sub-hazard ratio; CI, confidence interval. Bold indicates statistical significance. Hyperkalaemia is defined by
sK ≥ 5.0 mEq/L over the two study visits. Fine and Gray models are stratified by cohort and adjusted for variables at visit 2
(age, gender, diabetes, CV disease, BMI, haemoglobin, eGFR, 24 h proteinuria, systolic BP), RASI therapy over the two visits
and for eGFR change between the two study visits. The full model is shown in the Appendix (Table S2-Appendix).
Since underuse of RASI and persistent/new onset hyperkalaemia categories showed higher ESKD
risk (Table S2), we did an exploratory analysis evaluating the effect of combing hyperkalaemia and
RASI categories on patient outcome (Table 4); this analysis suggested that, as compared to reference
(absent or resolving hyperkalaemia combined with use of RASI), risk of ESKD significantly increases
by 57% when new-onset/persistent hyperkalaemia associates with non-use or discontinuation after
visit 1 of RASI. These results suggest a multiplicative effect of the two factors on ESKD risk. Conversely,
no effect on mortality risk of combination was found.
Table 4. Incidence and adjusted risk of ESKD in patients stratified in subgroups by the combination of
hyperkalaemia and RASI categories over the two study visits.
Hyperkalaemia RASI Incidence(events/pts)
Incidence Rate
(per 100-pts-y) sHR (95% CI) p
Absent/Resolving Yes 137/1.018 3.18 (2.67–3.75) Reference -
Absent/Resolving No 144/518 9.02 (7.61–10.62) 1.09 (0.83–1.44) 0.540
New onset/Persistent Yes 171/632 7.43 (6.36–8.63) 1.18 (0.94–1.49) 0.140
New onset/Persistent No 115/275 16.55 (13.67–19.87) 1.57 (1.20–2.06) 0.001
Hyperkalaemia defined by sK ≥ 5.0 mEq/L over the two study visits. sHR, sub-hazard ratio; CI, confidence
interval; RASI, inhibitors of renin-angiotensin system. Yes, RASI prescription at both visits or only visit 2; No, RASI
prescription at only visit 1 or at none of the two visits. The model is stratified by cohort and adjusted for variables
at visit 2 (age, gender, diabetes, CV disease, BMI, haemoglobin, eGFR, 24 h proteinuria, systolic BP) as for eGFR
change between the two study visit.
At variance with sK measured at visit 2, we did not detect any association of sK measured at
visit 1 with the subsequent incidence of ESKD (HR 1.04, 95% CI 0.90–1.20, p = 0.620). Also mortality
risk related to sK at visit 1 was not significant (0.97, 95% CI 0.79–1.19, p = 0.750). These results persisted
when adding the 370 patients initially excluded because of missed visit 2 (Table S3).
4. Discussion
We here provide insights into the true burden of hyperkalaemia in CKD patients under continuous
nephrology care. We add knowledge on this critical issue because we estimated prevalence of
hyperkalaemia using two sK tests with 12-month interval in a large sample of referred patients and
evaluated the association between hyperkalaemia and outcome by comprehensive survival analyses.
We found that moderate hyperkalaemia, as defined over two visits with 12-month interval, is common
J. Clin. Med. 2018, 7, 499 9 of 13
in ND-CKD patients under nephrology care, with a substantial portion of this population showing
new-onset or persistent hyperkalaemia over one year of observation. These patients showed higher
risk of ESKD, with no risk excess of death, in the subsequent 3.6 years-follow up.
Gaining insights into prevalence and prognostic role of hyperkalaemia in the setting of tertiary
nephrology care is important because nephrology clinics are the appropriate reference of care for
ND-CKD patients, as testified by favourable global prognosis in referred patients as compared to
those never or inconsistently followed by a nephrologist [23,32–36]. In this setting, improving risk
stratification is mandatory to optimize practice of nephrology workforce, which is limited today
and projected to further shrink in the next future [37]. Furthermore, at variance with unreferred
CKD, where death overcomes ESKD, the natural fate of CKD under nephrology care is progression to
ESKD [23–26,33–36,38–40]; in this regard, it is important to note that a recent survey among European
nephrologists has disclosed that in CKD stage 5 the main driver to start renal substitutive therapy
is the clinical picture, as currently recommended by international guidelines [41,42], with refractory
hyperkalaemia eliciting immediate dialysis start by 100% of interviewed nephrologists [43]. Finally,
hyperkalaemia is expected to be prevalent in this setting because nephrologists manage advanced
CKD and, moreover, prescribe RASI to prevent CKD progression [1–7,16–19,41,44].
We found high prevalence of hyperkalaemia in our patient population, with high sK detected in
as many as 54% patients in at least one of the two study visits. These figures are higher than previously
reported [1–7,15]. Nevertheless, our study is hardly comparable with early work not only in terms of
study setting but also for two features prevalent in renal clinics, that is, the low level of eGFR (77% had
CKD stages 4,5) and the high rate of RASI use (more than two-thirds at either visit). This latter feature
confirms the attitude of nephrologists toward maintenance of the only nephroprotective therapy today
available in advanced CKD [23,25,45,46]. In particular, analysis of the NephroTest cohort has showed
that prevalence of hyperkalaemia in ND-CKD was 6.5% [15]; however in that study patients were
more healthy (younger age, lower comorbidities and minor renal dysfunction) as compared with our
patients, and, in general with referred CKD patients. A likely reason is that additional and burdensome
work-up in Physiology Department was required for enrolment into NephroTest.
The observed high prevalence of hyperkalaemia reinforces the need of answering to the critical
question that remains unsolved so far, namely, as whether to what extent chronic hyperkalaemia
increases the risk of dialysis initiation. The previous studies evaluating the renal risk related to
hyperkalaemia have disclosed any or only weak association [1,4,10,13–15]. However, these earlier
data were mostly attained in settings other than outpatient renal clinics, often including patients with
preserved renal function and had short follow up. More important, no study has evaluated the ESKD
risk by properly evaluating the competing risk of death and adjusted analyses for the confounding
effect of eGFR decline.
We evaluated the effect of sK on ESKD risk by considering the competing risk of death before ESKD
and the potential confounder of GFR decline. Serum K was consistently identified as independent risk
factor of ESKD, when tested as continuous variable at visit 2 as well as sK change over the two visits.
The latter finding anticipates the result attained when examining hyperkalaemia categories, where
new-onset and persistent hyperkalaemia did portend a 30% higher risk of ESKD. Noteworthy, renal
risk related to hyperkalaemia was independent also from the eGFR change between the two visits,
thus excluding that it was merely dictated by the status of progressive CKD. Similarly, hyperkalaemia
risk was also independent from older age and diabetes, that are main determinants of hyperkalaemia
besides and beyond a low renal function [22].
Persistent or new-onset hyperkalaemia may also associate with lower use of RASI, that are the
key nephroprotective agents today available for ND-CKD, therefore indirectly increasing ESKD risk.
Although a cause-effect relationship can only be proven by a trial [46], it is interesting that a post-hoc
analysis of RENAAL trial in diabetic CKD patients has shown the nephroprotective efficacy of losartan
was in part offset by the hyperkalaemic effect of this drug [47]. Furthermore, a 8-week trial testing
a new K binder in hyperkalaemic ND-CKD patients showed that more patients could continue the
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nephroprotective therapy with ARB in the K-binder arm (95%) than in the placebo arm (50%) [48].
Our exploratory analysis (Table 4) showed that the ESKD risk increases in hyperkalaemic patients not
taking RASI on regular basis, thus suggesting that that the two factors should be examined jointly to a
proper assessment of the hyperkalaemia-driven risk in ND-CKD.
Interestingly, patient survival was not influenced by hyperkalaemia. Two potential reasons
may explain this finding. First, in our referred patients, ESKD overcomes mortality, as expected
in the tertiary nephrology care setting, and, second, nephrologists start dialysis in the presence of
hyperkalaemia, refractory to therapy, to prevent deaths related to potential additional increases of sK.
Of note, main limitation to this study is that determinants of hyperkalaemia could not be assessed
because profile of aldosterone/steroids, bicarbonate levels/supplementation and dietary K intake
were not available in most patients; however, analysis of determinants was not the aim of this outcome
study. On the other hand, strengths of the study are the sample size that is relatively large considering
the setting of tertiary nephrology care, the evaluation of ESKD risk that took into account the potential
confounder of death before ESKD and the adjustment for the extent of eGFR change that allows to
dissect the role of hyperkalaemia from that of GFR decline on ESKD onset.
5. Conclusions
In conclusion, our study provides evidence that in ND-CKD patients under stable nephrology care,
true mild-to-moderate hyperkalaemia (sK 5.0–6.0 mEq/L) is (I) common with 37% patients showing
new-onset or persistent hyperkalaemia over two visits with 12-month interval and (II) portends per se
a 30% higher risk of ESKD, that is independent from the rate of eGFR decline, while not affecting
patient survival.
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